sipuleucel-T
Generic: sipuleucel-T·Brand: Provenge
sipuleucel-T: 2 clinical trials tracked.
sipuleucel-T evidence translation
What we can confirm
2 tracked trials
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about sipuleucel-T, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (2)
A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Primary endpoint: Frequency of dose-limiting toxicities (Cohort 1 only)
Interventionalopen30 targetStarted 2026-11Completion 2031-011 site · United StatesWashington University School of Medicine
A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog
Primary endpoint: Cumulative APC Activation
InterventionalRandomizedopen26 targetStarted 2023-02Completion 2026-121 site · United StatesH. Lee Moffitt Cancer Center and Research Institute